News

Lighthouse Labs names new managing director

Lighthouse Labs has announced Art Espey as the new Managing Director, effective April 17. Art will replace outgoing Managing Director Paul Nolde, who will assume a similar role at Norfolk’s 757 Collab and 757 Angels organizations.

Art has long been involved with Lighthouse Labs, having previously served on the organization’s Board of Directors as Founding Vice Chair (2015 to 2018) and recently rejoining the Board. A serial entrepreneur, he has extensive experience in the full life cycle of startups, including scaling one of his ventures into a top 100 company in its industry with a staff of 500+, and gaining domestic and international leadership experience with an Inc. 500 company. His background includes work in healthcare, analytics, manufacturing, and construction, with significant experience in strategic leadership, private equity, diversity consulting, mergers and acquisitions, and business development. He holds degrees from the United States Merchant Marine Academy, Eastern Michigan University, and the University of Virginia. A former USMC Officer and Young Presidents’ Organization (YPO) member, Art has authored multiple books and taught a college-level course in change management. He currently sits on the Virginia Bio+Tech Partnership Authority Board of Directors and was formerly the Vice Chair of the American Red Cross in Southeastern Michigan. His wealth of experience will help Lighthouse Labs extend a record of success built on more than ten years of Investing in the lives of founders™. 

“After a decade, Lighthouse Labs is at an inflection point, with an opportunity to think big and reinvent our work with founders, investors, and the area’s innovation ecosystem,” Art shared. “I’m pleased to have the chance to build on the work previous leaders and the team have accomplished and look forward to continued success. I envision new and creative partnering opportunities with Paul and 757 Collab to foster innovation across the entire RVA757 megaregion.”

Nolde will continue with Lighthouse Labs through the end of the current cohort (May 30), and Art has already begun working with the team to ensure a smooth transition. Joe Kunkel, Lighthouse Labs Board Chair, stated “Lighthouse Labs has gained a stellar reputation and remained relevant by constantly refining our work to better support founders and their startups, and we are excited for the next chapter under Art’s leadership.”

 

Recent News

06/11/2026

Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing

Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that it has acquired Azora Therapeutics, Inc. (“Azora”), a biopharmaceutical company developing treatments for serious inflammatory diseases. The acquisition brings Azora’s lead asset AT177, a proprietary colon‑targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure, into Adial’s pipeline.

06/11/2026

Luna Labs Launches 3 Waves Venture Spinout to Commercialize Advanced Vestibular Stimulation Technology

Luna Labs today announced the launch of 3 Waves, Inc. (“3Waves”), a dual-use spinout company that was established to commercialize advanced virtual and mixed reality technologies for defense, commercial simulation, and medical applications. As part of the spinout, 3Waves and Mayo Clinic executed an exclusive license to support the development of next-generation vestibular stimulation systems

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and